Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136884 · ClinicalTrials.gov registry record · Phase 1
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A Phase 1 study of Solid Tumor Malignancies and Brain Metastases From Solid Tumors, sponsored by A2A Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 5
- Study locations
NCT06136884: Recruiting Phase 1 study of Solid Tumor Malignancies and Brain Metastases From Solid Tumors, sponsored by A2A Pharmaceuticals.
NCT06136884 is a Phase 1 study of Solid Tumor Malignancies and Brain Metastases From Solid Tumors that is actively recruiting participants, run by A2A Pharmaceuticals. The registered enrollment target is 86 participants, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (54% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06136884, a Phase 1 study of Solid Tumor Malignancies and Brain Metastases From Solid Tumors, is actively recruiting participants, sponsored by A2A Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Primary Outcome
Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects
Conditions Studied
Interventions
- DRUG AO-252
Study Locations (5)
Texas
- Mary Crowley Cancer Research - Dallas
- The University of Texas M.D. Anderson Cancer Center - Houston
Michigan
- Karmanos Cancer Institute - Detroit
Oklahoma
- Oklahoma Univeristy - Oklahoma City
Virginia
- Next Oncology -Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2028-01-27 |
| Phase | Phase 1 |
What NCT06136884 shows while recruiting
NCT06136884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AO-252 is the first listed.
NCT06136884 lists 5 locations in 4 states (Texas, Michigan, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT06136884 about?
NCT06136884 is a clinical study titled "A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases". The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
What is the current status of trial NCT06136884?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2023-11-02. Estimated completion is 2028-01-27.
What conditions does trial NCT06136884 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies, Brain Metastases From Solid Tumors.
What interventions are being tested in trial NCT06136884?
The interventions under investigation include: AO-252 (DRUG).
Who is sponsoring clinical trial NCT06136884?
This trial is sponsored by A2A Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136884 being conducted?
This trial has 5 study locations across Michigan, Oklahoma, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06136884's enrollment target sits among peer trials
86 8th of 11 higher than 4 of 11 other Solid Tumor Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI